Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent

Pediatr Neurol. 2022 Jan;126:9-10. doi: 10.1016/j.pediatrneurol.2021.10.003. Epub 2021 Oct 8.

Authors

Emily Malamud¹, Scott I Otallah², James B Caress³, Daniel J Lapid²

Affiliations

¹ Division of Pediatric Neurology, Department of Neurology, Wake Forest University/Brenner Children's Hospital, Winston-Salem, North Carolina. Electronic address: emalamud@wakehealth.edu.
² Division of Pediatric Neurology, Department of Neurology, Wake Forest University/Brenner Children's Hospital, Winston-Salem, North Carolina.
³ Division of Neuromuscular Disease, Department of Neurology, Wake Forest University, Winston-Salem, North Carolina.

PMID: 34717201
PMCID: PMC8498800
DOI: 10.1016/j.pediatrneurol.2021.10.003

No abstract available

Keywords: COVID-19 vaccine; Guillain-Barre syndrome; Pfizer; SARS-CoV-2 virus.

Publication types

Case Reports
Letter

MeSH terms

Adolescent
BNT162 Vaccine / adverse effects*
COVID-19 / prevention & control
Guillain-Barre Syndrome / chemically induced*
Guillain-Barre Syndrome / diagnosis*
Humans
Male

Substances

BNT162 Vaccine